Eli Lilly and its partner Daiichi Sankyo [1]Â moved swiftly to try and contain any damage from the news that they were suspending dosing in two small trials of the blood clot preventer prasugrel [2]--one of Lilly's most closely watched experimental programs. Officials insisted that the suspension--which was made to consider an adjustment of dosages for certain patients--would have no effect on their development timeline. That wasn't enough for investors, though, who pushed down Lilly's stock by four percent on the news. Prasrugel is considered a key program for Lilly's future, with the potential to compete against the blockbuster Sanofi-Aventis' Plavix--which earned $6 billion last year.
- see Lilly's release [3]Â on the suspended trial
- check out the report [4] from Forbes
Related Articles:
Lilly pits drug against Plavix in trial. Report [2]
Eli Lilly forges $1B diabetes deal. Report [5]
Daiichi aims for 60 percent growth. Report [1]
In speech, Lilly CEO calls for drug monitoring. Report [6]
Lilly developing biotech drugs the old-fashioned way. Report [7]
Links:
[1] http://www.fiercepharma.com/story/daiichi-aims-60-percent-growth/2007-10-02
[2] http://www.fiercebiotech.com/story/lilly-pits-experimental-drug-against-plavix-in-head-to-head-trial/2005-11-02
[3] http://www.fiercebiotech.com/press-releases/press-release-study-protocols-will-be-amended-two-small-early-phase-prasugrel-studies
[4] http://www.forbes.com/sciencesandmedicine/2007/10/24/pharmacuticals-lilly-prasugrel-biz-sci-cx_mh_1024lilly.html
[5] http://www.fiercebiotech.com/story/eli-lilly-forges-1b-diabetes-deal/2007-10-18?utm_medium=nl&utm_source=link
[6] http://www.fiercebiotech.com/story/speech-lilly-ceo-calls-drug-monitoring/2007-10-03
[7] http://www.fiercebiotech.com/story/lilly-developing-biotech-drugs-old-fashioned-way/2007-07-31